
Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as “good enough” to ease nerves about stiff competition from rival Eli Lilly (LLY).

Leave A Comment